Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AC-820; MT-9938; Nalfurafine hydrochloride; Nopicor; REMITCH; TRK-820; Winfuran

Latest Information Update: 25 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toray
  • Developer Fresenius Medical Care; Japan Tobacco; Maruho; Mitsubishi Tanabe Pharma Corporation; SK Chemicals; Toray; Torii Pharmaceutical
  • Class Antipruritics; Morphinans; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pruritus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pruritus
  • Discontinued Atopic dermatitis; Cancer pain; Neuropathic pain

Most Recent Events

  • 18 Jan 2019 Meiji Seika Pharma acquires the development and commercialisation rights to nalfurafine in Thailand and Indonesia
  • 16 Jan 2018 Sansheng Pharmaceutical acquires the development and commercialisation rights to nalfurafine in China (excluding Hong Kong, Macau and Taiwan)
  • 01 Jul 2017 Toray Industries completes a phase I trial in Pruritus in Bulgaria and Germany (PO) (NCT03002233)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top